Population genetic of Candida krusei isolated from yellow-legged gulls, southern France
Candida krusei is resistant-antifungal drugs pathogen, which is causing many infections in human. Yellow-legged gull was used as a model to study the distribution of C. krusei isolates in the south of France. MLVA approach was used to genotype 147 of C. krusei isolated from 111 fecal samples of gull colonies distributed in two cities Marseille and Montpellier. Thirty seven C. krusei genotypes were randomly distributed in gulls from two cities and the allele frequency test confirmed that the two C. krusei populations where share the same genotypes. In conclusion, Yellow-legged gulls consider as a good environmental reservoir of C. krusei isolates, which may be opportunist to infect human.
Al-Yasiri MH, Normand A-C, Piarroux R, Ranque S, Mauffrey J-F. 2016b. Gut yeast communities in Larus michahellis from various breeding colonies. Med Mycol. myw088, doi:10.1093/mmy/myw088.
Bonnedahl J, Drobni M, Gauthier-Clerc M, Hernandez J, Granholm S, Kayser Y, Melhus Å, Kahlmeter G, Waldenström J, Johansson A, Olsen B. 2009. Dissemination of Escherichia coli with CTX-M Type ESBL between Humans and Yellow-Legged Gulls in the South of France. PLoS ONE. 4:e5958, doi:10.1371/journal.pone.0005958.
Duhem C, Vidal E, Legrand J, Tatoni T. 2003. Opportunistic feeding responses of the Yellow-legged Gull Larus michahellis to accessibility of refuse dumps: The gulls adjust their diet composition and diversity according to refuse dump accessibility. Bird Study. 50:61–67, doi:10.1080/00063650309461291.
Güzel AB, Aydın M, Meral M, Kalkancı A, Ilkit M. 2013. Clinical Characteristics of Turkish Women with Candida krusei Vaginitis and Antifungal Susceptibility of the C. krusei Isolates. Infect Dis Obstet Gynecol. 2013:1–7, doi:10.1155/2013/698736.
Hagler AN, Mendonça-Hagler LC. 1981. Yeasts from marine and estuarine waters with different levels of pollution in the state of Rio de Janeiro, Brazil. Appl Environ Microbiol. 41:173–178.
Hazen KC. 1995. New and emerging yeast pathogens. Clin Microbiol Rev. 8:462–478.
Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, Dobiasova S, Rinaldi M, Barton R, Veselov A, Global Antifungal Surveillance Group. 2008a. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol. 46:515–521, doi:10.1128/JCM.01915-07.
Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, Dobiasova S, Rinaldi M, Barton R, Veselov A, the Global Antifungal Surveillance Group. 2008b. Candida krusei, a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol. 46:515–521, doi:10.1128/JCM.01915-07.
Reed KD, Meece JK, Henkel JS, Shukla SK. 2003. Birds, migration and emerging zoonoses: West Nile virus, Lyme disease, influenza A and enteropathogens. Clin Med Res. 1:5–12.
Samaranayake YH, Samaranayake LP. 1994. Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. J Med Microbiol. 41:295–310, doi:10.1099/00222615-41-5-295.
Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJS. 2013. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 62:10–24, doi:10.1099/jmm.0.045054-0.
Shemer R, Weissman Z, Hashman N, Kornitzer D. 2001. A highly polymorphic degenerate microsatellite for molecular strain typing of Candida krusei. Microbiology. 147:2021–2028.
Soll DR, Pujol C. 2003. Candida albicans clades. FEMS Immunol Med Microbiol. 39:1–7, doi:10.1016/S0928-8244(03)00242-6.